RZV offers substantial clinical and economic benefits but has low uptake among adults aged 50 and older compared to other vaccines. By 2020, only 10.8% of adults aged 50 and older had completed both ...

Japanese patients with vitiligo experienced lower quality of life and higher levels of anxiety and depression, especially when the disease affected their social life or had relapsed, according to a ...

Celecoxib improves disease-free and overall survival in ctDNA-positive stage III colon cancer patients when combined with ...

In another first, Sandoz launched in November 2025 the first FDA-approved biosimilar of Tysabri (natalizumab). Tyruko (natalizumab-sztn) is used to treat adult patients with relapsing multiple ...

As treatment for schizophrenia changes, LAIs are becoming increasingly important as maintenance therapy. Teva's pursuit of an ...

Teledermatology's growth in 2025 improved efficiency and accessibility, with virtual visits reducing costs and saving time for patients and doctors. Hybrid models combining live video and photo ...

The Managed Healthcare Executive 2025 State of the Industry survey is a timely snapshot of how payers, providers and pharmacy ...

A study of more than 1 million UK medical records found that getting a flu vaccine between ages 40 and 50 did not increase Parkinson’s disease risk and was even associated with a lower estimated ...

The IRA requires health plans serving the Part D market to cover all negotiated drugs, and it has been predicted that CMS ...

A new Tufts study found that Medicare price negotiations on biologics with imminent biosimilars could lead to near-term savings, but greater savings are likely from biosimilar competition.

High consumption of ultra-processed foods elevates the risk of early-onset colorectal cancer, highlighting the need for ...

An experimental monoclonal antibody called ianalumab had promising results for more than half of patients with primary immune thrombocytopenia enrolled in a phase 3 trial, according to data published ...